Abstract:Abstract INTRODUCTION: Despite the multitude of drug options, most patients with metastatic colorectal cancer (mCRC) die within 3 years of diagnosis. Response to systemic therapy is not durable (< 1year) and drug resistance is inevitable. There is accumulating evidence for the existence of cancer stem cells (CSCs) in CRC, which are now believed to mediate chemo-resistance. The molecular mechanisms that regulate the CSC phenotype in CRC have not been fully elucidated. The metalloproteinase ADAM17 [also known as TNFα-converting enzyme (TACE)], an enzyme involved in Notch pathway activation, has been shown to be overexpressed in CRC and mediate cell proliferation and chemo-resistance in CRC cells. However, the role of ADAM17 in mediating the CSC phenotype in CRC has not been characterized. The present study sought to determine the role of CRC-associated ADAM17 in mediating chemo-resistance of CRC cells by regulating the CSC phenotype. METHODS: Most preclinical studies used established cancer cell lines that have been cultured in vitro for decades. Our laboratory has shown that these cell lines are not suitable for consistent isolation of CSCs (Fan et al, 2014, BJC in press). To circumvent this problem, we developed a new model using CRC cells either freshly isolated from patient-derived xenografts (PDX) or early passage of newly established Human CRC Primary cell lines (HCP) derived from the PDXs. With this newly established HCP cell line model, we used siRNA knockdown or a synthetic peptide inhibitor TAPI-2, to determine the effect of blocking ADAM17 on the CSC phenotype and chemo-resistance in CRC cells. RESULTS: ADAM17 inhibition, either by siRNA or by TAPI-2, reduced the protein levels of cleaved Notch1 (NICD) and its downstream target HES-1 in CRC cells. Levels of proteins that are involved in other CSC-associated pathways were not altered by ADAM17 inhibition, suggesting that the Notch pathway is the major stem-cell pathway activated by ADAM17. Furthermore, ADAM17 inhibition caused a decrease in the CSC-phenotype in CRC cells as determined by the sphere formation assay and the Aldefluor assay (a standard assay for identifying CSCs). In addition, the lethal dose 50 (LD50) of 5-fluorouracil (5-FU) was decreased by 3 fold when pre-incubating CRC cells with the ADAM17 inhibitor TAPI-2. We also showed that the protein levels of ADAM17 were higher in our chemo-resistant cells (cells that survive continuous exposure to chemotherapy) compared to control. CONCLUSION: Our studies demonstrated the role of ADAM17 in promoting the CSC phenotype and chemo-resistance in CRC cells. Utilization of drugs that inhibit ADAM17 activity may increase the therapeutic benefit to patients with mCRC, and potentially other solid malignancies. Citation Format: Rui Wang, Fan Fan, Delphine Boulbes, Rajat Bhattacharya, Xiang-Cang Ye, Ling Xia, Lee Ellis. ADAM17 mediation of cancer stem cell-ness and chemo-resistance in colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2337. doi:10.1158/1538-7445.AM2015-2337

ADAMTS9 is Silenced by Epigenetic Disruption in Colorectal Cancer and Inhibits Cell Growth and Metastasis by Regulating Akt/p53 Signaling

A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling

Abstract 2337: ADAM17 Mediation of Cancer Stem Cell-Ness and Chemo-Resistance in Colorectal Cancer

ADAMTS9 is a Functional Tumor Suppressor Through Inhibiting AKT/mTOR Pathway and Associated with Poor Survival in Gastric Cancer

The 3p14.2 Tumour Suppressor ADAMTS9 is Inactivated by Promoter CpG Methylation and Inhibits Tumour Cell Growth in Breast Cancer.

Expression of ADAMTS12 in Colorectal Cancer-Associated Stroma Prevents Cancer Development and is a Good Prognostic Indicator of Colorectal Cancer

The expression of ADAMTS14 is regulated by promoter DNA methylation and is associated with poor prognosis in colorectal cancer

The Metalloprotease ADAMTS8 Displays Antitumor Properties Through Antagonizing EGFR–MEK–ERK Signaling and is Silenced in Carcinomas by CpG Methylation

Epigenetic silencing of ADAMTS5 is associated with increased invasiveness and poor survival in patients with colorectal cancer

ADAM9 Mediates Triple-Negative Breast Cancer Progression Via AKT/NF-κB Pathway.

Epigenetic Silencing of ADAMTS18 Promotes Cell Migration and Invasion of Breast Cancer Through AKT and NF‐κB Signaling

RNF180 Suppresses Methylation of ADAMTS9 DNA Promotor by Ubiquitinating DNMT3A Inhibiting Metastasis in Gastric Cancer

Methylation Status of ADAM12 Promoter Are Associated with Its Expression Levels in Colorectal Cancer.

DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells

Abstract 1116: the Role of ADAM9 and PI3K-dependent NF-kappa B Pathway in Promoting Metastasis of Triple-Negative Breast Cancer

Abstract. A disintegrin and metalloproteinase domain 9 (ADAM9) is a membrane-anchored protein implicated in cell-cell and cell-matrix interactions, including the process of tumorigenesis. However, the role of ADAM9 in gastric cancer

Inactivation Of Adamts18 By Aberrant Promoter Hypermethylation Contribute To Lung Cancer Progression

ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation Via Sequestering Mir-301B-3p.

High-resolution melting analysis of ADAMTS9 methylation levels in gastric, colorectal, and pancreatic cancers.

Metalloprotease ADAM9 Cleaves Ephrin-B Ligands and Differentially Regulates Wnt and Mtor Signaling Downstream of Akt Kinase in Colorectal Cancer Cells

Long Non‐coding RNA ADAMTS9‐AS1 Suppresses Colorectal Cancer by Inhibiting the Wnt/β‐catenin Signalling Pathway and is a Potential Diagnostic Biomarker